Downregulation of cell‐free miR‐198 as a diagnostic biomarker for lung adenocarcinoma‐associated malignant pleural effusion
Circulating cell‐free microRNAs (miRNAs) are potential cancer biomarkers. The aim of this study was to identify miRNAs that are differentially expressed between benign pleural effusion (BPE) and lung adenocarcinoma‐associated malignant pleural effusion (LA‐MPE). The expression level of cell‐free miR...
Saved in:
| Published in | International journal of cancer Vol. 133; no. 3; pp. 645 - 652 |
|---|---|
| Main Authors | , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Hoboken, NJ
Wiley-Blackwell
01.08.2013
Wiley Subscription Services, Inc |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Circulating cell‐free microRNAs (miRNAs) are potential cancer biomarkers. The aim of this study was to identify miRNAs that are differentially expressed between benign pleural effusion (BPE) and lung adenocarcinoma‐associated malignant pleural effusion (LA‐MPE). The expression level of cell‐free miRNA was investigated in 107 patients with pleural effusion. Microarrays were used to screen 160 miRNAs in a discovery set comprising 20 effusion samples (ten BPEs and ten LA‐MPEs). Real‐time quantitative reverse transcription polymerase chain reaction (qRT‐PCR) was used to validate the profiling results obtained for the discovery set and those obtained for a validation set comprising 42 BPEs and 45 LA‐MPEs. The area under the receiver operating characteristic curve (AUC) was used to evaluate the diagnostic performance of the identified miRNAs and other common tumor markers, such as carcinoembryonic antigen (CEA) and cytokeratin fragment (CYFRA) 21‐1. Microarray profiling showed that miR‐198 was significantly downregulated in LA‐MPE compared with BPE (p = 0.002). The miRNA microarray analysis results were confirmed by qRT‐PCR (p < 0.001) using the validation set. The AUCs for miR‐198, CEA and CYFRA 21‐1 in the validation set were 0.887, 0.898 and 0.836, respectively. The diagnostic performance of miR‐198 was comparable with that of CEA, but better than that of CYFRA 21‐1. The AUC for all three markers combined was 0.926 (95% confidence interval, 0.843–0.973) with a sensitivity of 89.2% and a specificity of 85.0%. The present study suggests that cell‐free miR‐198 from patients with pleural effusion might have diagnostic potential for differentiating LA‐MPE from BPE.
What's new?
Short bits of regulatory RNA called miRNAs circulate in the blood, and they sometimes prove useful for diagnosing cancers. This study investigated whether miRNAs could help distinguish between benign and cancer‐related fluid build‐up in the lungs. One miRNA, miR‐198, was expressed much less in samples from patients with the pre‐cancerous condition than those whose fluid accumulation was benign. When they quantified miR‐198's predictive ability, the authors found that it performed as well or better than two common cancer markers, CEA and CYFRA. The newly identified miRNA, therefore, could be quite handy for diagnosing lung adenocarcinomas. |
|---|---|
| AbstractList | Circulating cell-free microRNAs (miRNAs) are potential cancer biomarkers. The aim of this study was to identify miRNAs that are differentially expressed between benign pleural effusion (BPE) and lung adenocarcinoma-associated malignant pleural effusion (LA-MPE). The expression level of cell-free miRNA was investigated in 107 patients with pleural effusion. Microarrays were used to screen 160 miRNAs in a discovery set comprising 20 effusion samples (ten BPEs and ten LA-MPEs). Real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) was used to validate the profiling results obtained for the discovery set and those obtained for a validation set comprising 42 BPEs and 45 LA-MPEs. The area under the receiver operating characteristic curve (AUC) was used to evaluate the diagnostic performance of the identified miRNAs and other common tumor markers, such as carcinoembryonic antigen (CEA) and cytokeratin fragment (CYFRA) 21-1. Microarray profiling showed that miR-198 was significantly downregulated in LA-MPE compared with BPE (p = 0.002). The miRNA microarray analysis results were confirmed by qRT-PCR (p < 0.001) using the validation set. The AUCs for miR-198, CEA and CYFRA 21-1 in the validation set were 0.887, 0.898 and 0.836, respectively. The diagnostic performance of miR-198 was comparable with that of CEA, but better than that of CYFRA 21-1. The AUC for all three markers combined was 0.926 (95% confidence interval, 0.843-0.973) with a sensitivity of 89.2% and a specificity of 85.0%. The present study suggests that cell-free miR-198 from patients with pleural effusion might have diagnostic potential for differentiating LA-MPE from BPE. Circulating cell‐free microRNAs (miRNAs) are potential cancer biomarkers. The aim of this study was to identify miRNAs that are differentially expressed between benign pleural effusion (BPE) and lung adenocarcinoma‐associated malignant pleural effusion (LA‐MPE). The expression level of cell‐free miRNA was investigated in 107 patients with pleural effusion. Microarrays were used to screen 160 miRNAs in a discovery set comprising 20 effusion samples (ten BPEs and ten LA‐MPEs). Real‐time quantitative reverse transcription polymerase chain reaction (qRT‐PCR) was used to validate the profiling results obtained for the discovery set and those obtained for a validation set comprising 42 BPEs and 45 LA‐MPEs. The area under the receiver operating characteristic curve (AUC) was used to evaluate the diagnostic performance of the identified miRNAs and other common tumor markers, such as carcinoembryonic antigen (CEA) and cytokeratin fragment (CYFRA) 21‐1. Microarray profiling showed that miR‐198 was significantly downregulated in LA‐MPE compared with BPE (p = 0.002). The miRNA microarray analysis results were confirmed by qRT‐PCR (p < 0.001) using the validation set. The AUCs for miR‐198, CEA and CYFRA 21‐1 in the validation set were 0.887, 0.898 and 0.836, respectively. The diagnostic performance of miR‐198 was comparable with that of CEA, but better than that of CYFRA 21‐1. The AUC for all three markers combined was 0.926 (95% confidence interval, 0.843–0.973) with a sensitivity of 89.2% and a specificity of 85.0%. The present study suggests that cell‐free miR‐198 from patients with pleural effusion might have diagnostic potential for differentiating LA‐MPE from BPE. What's new? Short bits of regulatory RNA called miRNAs circulate in the blood, and they sometimes prove useful for diagnosing cancers. This study investigated whether miRNAs could help distinguish between benign and cancer‐related fluid build‐up in the lungs. One miRNA, miR‐198, was expressed much less in samples from patients with the pre‐cancerous condition than those whose fluid accumulation was benign. When they quantified miR‐198's predictive ability, the authors found that it performed as well or better than two common cancer markers, CEA and CYFRA. The newly identified miRNA, therefore, could be quite handy for diagnosing lung adenocarcinomas. Circulating cell-free microRNAs (miRNAs) are potential cancer biomarkers. The aim of this study was to identify miRNAs that are differentially expressed between benign pleural effusion (BPE) and lung adenocarcinoma-associated malignant pleural effusion (LA-MPE). The expression level of cell-free miRNA was investigated in 107 patients with pleural effusion. Microarrays were used to screen 160 miRNAs in a discovery set comprising 20 effusion samples (ten BPEs and ten LA-MPEs). Real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) was used to validate the profiling results obtained for the discovery set and those obtained for a validation set comprising 42 BPEs and 45 LA-MPEs. The area under the receiver operating characteristic curve (AUC) was used to evaluate the diagnostic performance of the identified miRNAs and other common tumor markers, such as carcinoembryonic antigen (CEA) and cytokeratin fragment (CYFRA) 21-1. Microarray profiling showed that miR-198 was significantly downregulated in LA-MPE compared with BPE (p=0.002). The miRNA microarray analysis results were confirmed by qRT-PCR (p<0.001) using the validation set. The AUCs for miR-198, CEA and CYFRA 21-1 in the validation set were 0.887, 0.898 and 0.836, respectively. The diagnostic performance of miR-198 was comparable with that of CEA, but better than that of CYFRA 21-1. The AUC for all three markers combined was 0.926 (95% confidence interval, 0.843-0.973) with a sensitivity of 89.2% and a specificity of 85.0%. The present study suggests that cell-free miR-198 from patients with pleural effusion might have diagnostic potential for differentiating LA-MPE from BPE. What's new? Short bits of regulatory RNA called miRNAs circulate in the blood, and they sometimes prove useful for diagnosing cancers. This study investigated whether miRNAs could help distinguish between benign and cancer-related fluid build-up in the lungs. One miRNA, miR-198, was expressed much less in samples from patients with the pre-cancerous condition than those whose fluid accumulation was benign. When they quantified miR-198's predictive ability, the authors found that it performed as well or better than two common cancer markers, CEA and CYFRA. The newly identified miRNA, therefore, could be quite handy for diagnosing lung adenocarcinomas. [PUBLICATION ABSTRACT] Circulating cell‐free microRNAs (miRNAs) are potential cancer biomarkers. The aim of this study was to identify miRNAs that are differentially expressed between benign pleural effusion (BPE) and lung adenocarcinoma‐associated malignant pleural effusion (LA‐MPE). The expression level of cell‐free miRNA was investigated in 107 patients with pleural effusion. Microarrays were used to screen 160 miRNAs in a discovery set comprising 20 effusion samples (ten BPEs and ten LA‐MPEs). Real‐time quantitative reverse transcription polymerase chain reaction (qRT‐PCR) was used to validate the profiling results obtained for the discovery set and those obtained for a validation set comprising 42 BPEs and 45 LA‐MPEs. The area under the receiver operating characteristic curve (AUC) was used to evaluate the diagnostic performance of the identified miRNAs and other common tumor markers, such as carcinoembryonic antigen (CEA) and cytokeratin fragment (CYFRA) 21‐1. Microarray profiling showed that miR‐198 was significantly downregulated in LA‐MPE compared with BPE ( p = 0.002). The miRNA microarray analysis results were confirmed by qRT‐PCR ( p < 0.001) using the validation set. The AUCs for miR‐198, CEA and CYFRA 21‐1 in the validation set were 0.887, 0.898 and 0.836, respectively. The diagnostic performance of miR‐198 was comparable with that of CEA, but better than that of CYFRA 21‐1. The AUC for all three markers combined was 0.926 (95% confidence interval, 0.843–0.973) with a sensitivity of 89.2% and a specificity of 85.0%. The present study suggests that cell‐free miR‐198 from patients with pleural effusion might have diagnostic potential for differentiating LA‐MPE from BPE. What's new? Short bits of regulatory RNA called miRNAs circulate in the blood, and they sometimes prove useful for diagnosing cancers. This study investigated whether miRNAs could help distinguish between benign and cancer‐related fluid build‐up in the lungs. One miRNA, miR‐198, was expressed much less in samples from patients with the pre‐cancerous condition than those whose fluid accumulation was benign. When they quantified miR‐198's predictive ability, the authors found that it performed as well or better than two common cancer markers, CEA and CYFRA. The newly identified miRNA, therefore, could be quite handy for diagnosing lung adenocarcinomas. Circulating cell-free microRNAs (miRNAs) are potential cancer biomarkers. The aim of this study was to identify miRNAs that are differentially expressed between benign pleural effusion (BPE) and lung adenocarcinoma-associated malignant pleural effusion (LA-MPE). The expression level of cell-free miRNA was investigated in 107 patients with pleural effusion. Microarrays were used to screen 160 miRNAs in a discovery set comprising 20 effusion samples (ten BPEs and ten LA-MPEs). Real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) was used to validate the profiling results obtained for the discovery set and those obtained for a validation set comprising 42 BPEs and 45 LA-MPEs. The area under the receiver operating characteristic curve (AUC) was used to evaluate the diagnostic performance of the identified miRNAs and other common tumor markers, such as carcinoembryonic antigen (CEA) and cytokeratin fragment (CYFRA) 21-1. Microarray profiling showed that miR-198 was significantly downregulated in LA-MPE compared with BPE (p = 0.002). The miRNA microarray analysis results were confirmed by qRT-PCR (p < 0.001) using the validation set. The AUCs for miR-198, CEA and CYFRA 21-1 in the validation set were 0.887, 0.898 and 0.836, respectively. The diagnostic performance of miR-198 was comparable with that of CEA, but better than that of CYFRA 21-1. The AUC for all three markers combined was 0.926 (95% confidence interval, 0.843-0.973) with a sensitivity of 89.2% and a specificity of 85.0%. The present study suggests that cell-free miR-198 from patients with pleural effusion might have diagnostic potential for differentiating LA-MPE from BPE. |
| Author | Kim, Wun‐Jae Yun, Seok Joong Lim, Sung‐nam Son, Seung‐Myoung Kim, Seung Taik Lee, Ok‐Jun Han, Hye‐Suk Lee, Yong‐Moon Choi, Song‐Yi Kang, Min‐Ho Han, Joung‐Ho Lee, Ki Hyeong Yun, Jieun |
| Author_xml | – sequence: 1 givenname: Hye‐Suk surname: Han fullname: Han, Hye‐Suk organization: Chungbuk National University – sequence: 2 givenname: Jieun surname: Yun fullname: Yun, Jieun organization: Korea Research Institute of Bioscience and Biotechnology – sequence: 3 givenname: Sung‐nam surname: Lim fullname: Lim, Sung‐nam organization: Chungbuk National University – sequence: 4 givenname: Joung‐Ho surname: Han fullname: Han, Joung‐Ho organization: Chungbuk National University – sequence: 5 givenname: Ki Hyeong surname: Lee fullname: Lee, Ki Hyeong organization: Chungbuk National University – sequence: 6 givenname: Seung Taik surname: Kim fullname: Kim, Seung Taik organization: Chungbuk National University – sequence: 7 givenname: Min‐Ho surname: Kang fullname: Kang, Min‐Ho organization: Chungbuk National University – sequence: 8 givenname: Seung‐Myoung surname: Son fullname: Son, Seung‐Myoung organization: Chungbuk National University – sequence: 9 givenname: Yong‐Moon surname: Lee fullname: Lee, Yong‐Moon organization: Chungbuk National University – sequence: 10 givenname: Song‐Yi surname: Choi fullname: Choi, Song‐Yi organization: Chungbuk National University – sequence: 11 givenname: Seok Joong surname: Yun fullname: Yun, Seok Joong organization: Chungbuk National University – sequence: 12 givenname: Wun‐Jae surname: Kim fullname: Kim, Wun‐Jae organization: Chungbuk National University – sequence: 13 givenname: Ok‐Jun surname: Lee fullname: Lee, Ok‐Jun organization: Chungbuk National University |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27406508$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/23354517$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kVFrFDEQx4O02Ovpg19AAiLow7bJJpvdfSxn1ZaCIPq8zGYnR85scia7lL7pN-hn9JOY864KBZ9mYH4z_5n5n5IjHzwS8oKzM85YeW43-qxsWCWfkAVnbV2wkldHZJFrrKi5UCfkNKUNY5xXTD4lJ6UQlax4vSA_34VbH3E9O5hs8DQYqtG5Xz_uTUSko_2cU942FBIFOlhY-5Amq2lvwwjxG0ZqQqRu9msKA_qgIWrrcy33QUpBW5hwoCM4u_bgJ7p1OEdwFI2ZU5Z8Ro4NuITPD3FJvr6__LL6WNx8-nC1urgptJStLBqBQkLLxKCw7_kgmTSm5Nr0KAzHQUhuANtSNUqxCkFKqdre9HroZWlKJZbkzX7uNobvM6apG23a3Qoew5w6nl9St1yxOqOvHqGbMEeft-u4FIKXaheW5O2e0jGkFNF022jzT-46zrqdL132pfvjS2ZfHibO_YjDX_LBiAy8PgCQNDgTwWub_nG1ZKpiTebO99ytdXj3f8Xu6nq1l_4Nyaupvg |
| CODEN | IJCNAW |
| CitedBy_id | crossref_primary_10_3233_CBM_210090 crossref_primary_10_1515_hsz_2018_0303 crossref_primary_10_3892_ol_2019_10610 crossref_primary_10_1515_pp_2016_0001 crossref_primary_10_1016_j_trac_2020_115900 crossref_primary_10_1186_s12943_016_0536_0 crossref_primary_10_4143_crt_2014_46_2_178 crossref_primary_10_1016_j_addr_2014_09_001 crossref_primary_10_1080_15384101_2018_1558860 crossref_primary_10_1186_s12957_018_1320_y crossref_primary_10_1373_clinchem_2015_241190 crossref_primary_10_1002_jcb_24742 crossref_primary_10_1007_s43032_021_00717_w crossref_primary_10_1038_nrclinonc_2017_14 crossref_primary_10_3390_ijms24119748 crossref_primary_10_1002_jcla_24777 crossref_primary_10_3892_etm_2019_7276 crossref_primary_10_1093_icvts_ivx327 crossref_primary_10_1016_j_critrevonc_2019_06_005 crossref_primary_10_1177_1010428317706430 crossref_primary_10_2217_bmm_14_102 crossref_primary_10_1002_jcp_26095 crossref_primary_10_1007_s11325_024_02992_8 crossref_primary_10_1515_cclm_2022_0844 crossref_primary_10_3389_fbioe_2022_797900 crossref_primary_10_1371_journal_pone_0153046 crossref_primary_10_2147_OTT_S371629 crossref_primary_10_1186_1756_9966_32_59 crossref_primary_10_2174_1871520621666210608094908 crossref_primary_10_3892_ol_2014_2404 crossref_primary_10_3390_ijms241713302 crossref_primary_10_3390_ijms140510307 crossref_primary_10_1517_14712598_2014_882896 crossref_primary_10_1007_s10147_016_1073_y crossref_primary_10_1007_s10787_020_00698_3 crossref_primary_10_3892_ol_2015_3610 crossref_primary_10_3390_cancers13112798 crossref_primary_10_18632_aging_203303 crossref_primary_10_3390_ijms19020595 crossref_primary_10_1515_cclm_2022_0519 crossref_primary_10_3390_ijms17040494 crossref_primary_10_2217_bmm_2021_0370 crossref_primary_10_1007_s13665_015_0104_x crossref_primary_10_1016_j_prp_2021_153741 crossref_primary_10_3390_diagnostics11030421 crossref_primary_10_1002_dc_24392 crossref_primary_10_1016_j_bbrc_2016_03_040 crossref_primary_10_1002_cncy_22143 crossref_primary_10_1002_jcb_27204 crossref_primary_10_3390_genes9030139 crossref_primary_10_2174_1566523221666211202095258 crossref_primary_10_1002_jcp_24806 crossref_primary_10_1038_srep06145 crossref_primary_10_1111_cpr_12262 |
| Cites_doi | 10.1373/clinchem.2010.147405 10.1371/journal.pone.0038248 10.1016/S0065-2660(06)56001-8 10.1016/j.febslet.2010.08.009 10.1038/nrclinonc.2011.76 10.1023/A:1023768811842 10.1183/09031936.06.00013706 10.1016/j.febslet.2011.05.042 10.1007/s10620-011-1981-7 10.2217/fon.11.74 10.1002/gcc.20604 10.1016/j.bbcan.2009.11.003 10.1016/j.mrfmmm.2011.04.002 10.1373/clinchem.2008.112797 10.1158/0008-5472.CAN-08-1643 10.3389/fgene.2011.00007 10.1016/j.rmed.2010.08.005 10.1371/journal.pone.0039309 10.1002/hep.22158 10.1016/S0092-8674(04)00045-5 10.1515/CCLM.2011.661 10.3322/caac.20107 10.1183/09031936.01.00225601 10.3233/CBM-2009-0131 10.1186/gb-2009-10-6-r64 10.1038/nature02871 10.1634/theoncologist.10-7-501 10.1186/1471-2199-9-76 10.1002/jcla.20208 10.1016/j.lungcan.2011.06.004 10.1016/j.lungcan.2011.07.008 10.1016/S0140-6736(03)13079-6 10.1016/j.biocel.2009.12.014 10.1186/1471-2407-10-591 10.1016/j.mrfmmm.2011.03.004 10.1016/j.coph.2010.05.010 10.1097/JTO.0b013e3182417e44 10.1038/sj.bjc.6606076 10.1586/era.11.197 10.1016/j.clinbiochem.2010.11.002 10.2174/1381612013397087 10.3109/00313021003631320 10.1002/ijc.25285 |
| ContentType | Journal Article |
| Copyright | Copyright © 2013 UICC 2014 INIST-CNRS Copyright © 2013 UICC. |
| Copyright_xml | – notice: Copyright © 2013 UICC – notice: 2014 INIST-CNRS – notice: Copyright © 2013 UICC. |
| DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7T5 7TO 7U9 H94 K9. 7X8 |
| DOI | 10.1002/ijc.28054 |
| DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Immunology Abstracts Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Virology and AIDS Abstracts Oncogenes and Growth Factors Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic AIDS and Cancer Research Abstracts CrossRef MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1097-0215 |
| EndPage | 652 |
| ExternalDocumentID | 3074014201 10_1002_ijc_28054 23354517 27406508 IJC28054 |
| Genre | article Research Support, Non-U.S. Gov't Journal Article Feature |
| GrantInformation_xml | – fundername: Basic Science Research Program [through the National Research Foundation of Korea (NRF), funded by Ministry of Education, Science and Technology] funderid: 2012–0005754 |
| GroupedDBID | --- -~X .3N .GA .Y3 05W 0R~ 10A 1L6 1OB 1OC 1ZS 24P 33P 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 5GY 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAXRX AAZKR ABCQN ABCUV ABIJN ABJNI ABLJU ABOCM ABPVW ABQWH ABXGK ACAHQ ACCFJ ACCZN ACFBH ACGFO ACGFS ACGOF ACIWK ACMXC ACPOU ACPRK ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFRAH AFZJQ AHBTC AHMBA AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBS EJD EMOBN F00 F01 F04 F5P FUBAC G-S G.N GNP GODZA H.X HBH HGLYW HHY HHZ HZ~ IH2 IX1 J0M JPC KBYEO KQQ L7B LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D PQQKQ Q.N Q11 QB0 QRW R.K RIWAO RJQFR ROL RWI RX1 RYL SUPJJ TEORI UB1 UDS V2E V8K V9Y W2D W8V W99 WBKPD WHWMO WIB WIH WIJ WIK WIN WJL WOHZO WQJ WRC WUP WVDHM WWO WXI WXSBR XG1 XPP XV2 ZZTAW ~IA ~WT .55 .GJ 31~ 3O- 53G 8WZ A6W AAJUZ AAPBV AAVGM ABCVL ABEFU ABEML ABFLS ABHUG ABWRO ACBWZ ACSCC ACSMX ACXME ADAWD ADDAD ADGIM AFVGU AGJLS AHEFC AI. ASPBG AVWKF AZFZN BDRZF EX3 FEDTE GLUZI HF~ HVGLF IPNFZ IQODW M6P PALCI PQEST SAMSI VH1 WOW X7M Y6R ZGI ZXP CGR CUY CVF ECM EIF NPM AAYXX CITATION 7T5 7TO 7U9 H94 K9. 7X8 |
| ID | FETCH-LOGICAL-c4494-83e34a903d6ebb1d404ff21cfbe3f1ed341fae92686605ea44469bfbcdb42f263 |
| IEDL.DBID | DR2 |
| ISSN | 0020-7136 |
| IngestDate | Fri Aug 16 11:57:12 EDT 2024 Thu Oct 10 17:14:36 EDT 2024 Fri Aug 23 01:23:13 EDT 2024 Sat Sep 28 08:34:08 EDT 2024 Fri Nov 25 01:08:14 EST 2022 Sat Aug 24 01:08:35 EDT 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | Lung disease Respiratory disease Lung cancer lung adenocarcinoma Pleural effusion Biological marker Cytokeratin 19 Malignant tumor Bronchopulmonary adenocarcinoma Malignant pleural effusion Cancerology miR-198 Pleurisy Pleural disease Bronchus disease Diagnosis Cell free system CYFRA 21-1 CEA Cancer |
| Language | English |
| License | CC BY 4.0 Copyright © 2013 UICC. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4494-83e34a903d6ebb1d404ff21cfbe3f1ed341fae92686605ea44469bfbcdb42f263 |
| Notes | H.‐S.H. and J.Y. contributed equally to the work. This article was published online on 25 February 2013. An error was subsequently identified. This notice is included in the online and print versions to indicate that both have been corrected 28 May 2013. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 23354517 |
| PQID | 1433126143 |
| PQPubID | 105430 |
| PageCount | 8 |
| ParticipantIDs | proquest_miscellaneous_1354791607 proquest_journals_1433126143 crossref_primary_10_1002_ijc_28054 pubmed_primary_23354517 pascalfrancis_primary_27406508 wiley_primary_10_1002_ijc_28054_IJC28054 |
| PublicationCentury | 2000 |
| PublicationDate | 1 August 2013 |
| PublicationDateYYYYMMDD | 2013-08-01 |
| PublicationDate_xml | – month: 08 year: 2013 text: 1 August 2013 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Hoboken, NJ |
| PublicationPlace_xml | – name: Hoboken, NJ – name: United States – name: Hoboken |
| PublicationTitle | International journal of cancer |
| PublicationTitleAlternate | Int J Cancer |
| PublicationYear | 2013 |
| Publisher | Wiley-Blackwell Wiley Subscription Services, Inc |
| Publisher_xml | – name: Wiley-Blackwell – name: Wiley Subscription Services, Inc |
| References | 1991; 4 2010; 56 2010; 10 2011; 2 2006; 56 2011; 717 2010; 127 2010; 104 2000; 41 2011; 61 2008; 9 2012; 57 2012; 12 2011; 8 2011; 7 2012; 75 2004; 431 2009; 55 2011; 104 2010; 42 2004; 116 2009; 10 2001; 7 2006; 28 2008; 47 2011; 44 2005; 10 2008; 68 2001; 18 2010; 1805 2007; 21 2011; 49 2012; 7 2011; 585 2010; 6 2003; 22 2003; 361 e_1_2_7_4_1 e_1_2_7_3_1 e_1_2_7_9_1 e_1_2_7_8_1 e_1_2_7_7_1 e_1_2_7_19_1 e_1_2_7_18_1 e_1_2_7_17_1 e_1_2_7_16_1 e_1_2_7_40_1 e_1_2_7_2_1 e_1_2_7_15_1 e_1_2_7_41_1 e_1_2_7_14_1 e_1_2_7_42_1 Ong KC (e_1_2_7_6_1) 2000; 41 e_1_2_7_13_1 e_1_2_7_43_1 e_1_2_7_12_1 e_1_2_7_44_1 e_1_2_7_11_1 e_1_2_7_45_1 e_1_2_7_10_1 e_1_2_7_46_1 e_1_2_7_26_1 e_1_2_7_27_1 e_1_2_7_28_1 e_1_2_7_29_1 Fleischhacker M (e_1_2_7_23_1) 2010; 6 Nance KV (e_1_2_7_5_1) 1991; 4 e_1_2_7_30_1 e_1_2_7_25_1 e_1_2_7_31_1 e_1_2_7_24_1 e_1_2_7_32_1 e_1_2_7_33_1 e_1_2_7_22_1 e_1_2_7_34_1 e_1_2_7_21_1 e_1_2_7_35_1 e_1_2_7_20_1 e_1_2_7_36_1 e_1_2_7_37_1 e_1_2_7_38_1 e_1_2_7_39_1 |
| References_xml | – volume: 4 start-page: 320 year: 1991 end-page: 4 article-title: Diagnostic efficacy of pleural biopsy as compared with that of pleural fluid examination publication-title: Mod Pathol – volume: 7 start-page: e39309 year: 2012 article-title: Reference miRNAs for miRNAome analysis of urothelial carcinomas publication-title: PLoS One – volume: 47 start-page: 1025 year: 2008 end-page: 37 article-title: Expression and mutational analysis of MET in human solid cancers publication-title: Genes Chromosomes Cancer – volume: 55 start-page: 611 year: 2009 end-page: 22 article-title: The MIQE guidelines: minimum information for publication of quantitative real‐time PCR experiments publication-title: Clin Chem – volume: 104 start-page: 1168 year: 2011 end-page: 77 article-title: The small‐nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis publication-title: Br J Cancer – volume: 18 start-page: 402 year: 2001 end-page: 19 article-title: Management of malignant pleural effusions publication-title: Eur Respir J – volume: 585 start-page: 2087 year: 2011 end-page: 99 article-title: Dysregulation of microRNAs in cancer: playing with fire publication-title: FEBS Lett – volume: 361 start-page: 1326 year: 2003 end-page: 30 article-title: Standard pleural biopsy versus CT‐guided cutting‐needle biopsy for diagnosis of malignant disease in pleural effusions: a randomised controlled trial publication-title: Lancet – volume: 56 start-page: 1733 year: 2010 end-page: 41 article-title: The microRNA spectrum in 12 body fluids publication-title: Clin Chem – volume: 1805 start-page: 209 year: 2010 end-page: 17 article-title: As in cancer ‐ from research to therapy publication-title: Biochim Biophys Acta – volume: 717 start-page: 25 year: 2011 end-page: 31 article-title: MicroRNA in lung cancer diagnostics and treatment publication-title: Mutat Res – volume: 10 start-page: R64 year: 2009 article-title: A novel and universal method for microRNA RT‐qPCR data normalization publication-title: Genome Biol – volume: 10 start-page: 501 year: 2005 end-page: 7 article-title: Diagnostic value of CYFRA 21‐1, CEA, CA 19‐9, CA 15‐3, and CA 125 assays in pleural effusions: analysis of 116 cases and review of the literature publication-title: Oncologist – volume: 116 start-page: 281 year: 2004 end-page: 97 article-title: MicroRNAs: genomics, biogenesis, mechanism, and function publication-title: Cell – volume: 75 start-page: 89 year: 2012 end-page: 94 article-title: Co‐existence of positive MET FISH status with EGFR mutations signifies poor prognosis in lung adenocarcinoma patients publication-title: Lung Cancer – volume: 41 start-page: 19 year: 2000 end-page: 23 article-title: The diagnostic yield of pleural fluid cytology in malignant pleural effusions publication-title: Singapore Med J – volume: 10 start-page: 543 year: 2010 end-page: 50 article-title: MiRNAs as biomarkers and therapeutic targets in cancer publication-title: Curr Opin Pharmacol – volume: 49 start-page: 1591 year: 2011 end-page: 603 article-title: Prognostic, therapeutic and diagnostic potential of microRNAs in non‐small cell lung cancer publication-title: Clin Chem Lab Med – volume: 61 start-page: 69 year: 2011 end-page: 90 article-title: Global cancer statistics publication-title: CA Cancer J Clin – volume: 10 start-page: 591 year: 2010 article-title: Cell‐free miRNAs may indicate diagnosis and docetaxel sensitivity of tumor cells in malignant effusions publication-title: BMC Cancer – volume: 6 start-page: 211 year: 2010 end-page: 9 article-title: Free circulating nucleic acids in plasma and serum (CNAPS) -- Useful for the detection of lung cancer patients? publication-title: Cancer Biomark – volume: 2 start-page: 7 year: 2011 article-title: Circulating MicroRNAs as Minimally Invasive Biomarkers for Cancer Theragnosis and Prognosis publication-title: Front Genet – volume: 585 start-page: 2229 year: 2011 end-page: 34 article-title: miR‐198 inhibits migration and invasion of hepatocellular carcinoma cells by targeting the HGF/c‐MET pathway publication-title: FEBS Lett – volume: 431 start-page: 350 year: 2004 end-page: 5 article-title: The functions of animal microRNAs publication-title: Nature – volume: 12 start-page: 283 year: 2012 end-page: 8 article-title: Circulating microRNAs in cancer: diagnostic and prognostic significance publication-title: Expert Rev Anticancer Ther – volume: 8 start-page: 467 year: 2011 end-page: 77 article-title: MicroRNAs in body fluids--the mix of hormones and biomarkers publication-title: Nat Rev Clin Oncol – volume: 28 start-page: 409 year: 2006 end-page: 22 article-title: Thoracoscopy: general overview and place in the diagnosis and management of pleural effusion publication-title: Eur Respir J – volume: 75 start-page: 181 year: 2012 end-page: 8 article-title: Abnormality of the hepatocyte growth factor/MET pathway in pulmonary adenocarcinogenesis publication-title: Lung Cancer – volume: 717 start-page: 85 year: 2011 end-page: 90 article-title: Extracellular microRNA: a new source of biomarkers publication-title: Mutat Res – volume: 9 start-page: 76 year: 2008 article-title: Identification of suitable endogenous control genes for microRNA gene expression analysis in human breast cancer publication-title: BMC Mol Biol – volume: 7 start-page: 1839 year: 2001 end-page: 62 article-title: Peptide‐nucleic acids (PNAs): a tool for the development of gene expression modifiers publication-title: Curr Pharm Des – volume: 42 start-page: 1273 year: 2010 end-page: 81 article-title: MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy publication-title: Int J Biochem Cell Biol – volume: 47 start-page: 1223 year: 2008 end-page: 32 article-title: MicroRNA gene expression profile of hepatitis C virus‐associated hepatocellular carcinoma publication-title: Hepatology – volume: 68 start-page: 9479 year: 2008 end-page: 87 article-title: Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor‐activating mutations publication-title: Cancer Res – volume: 57 start-page: 897 year: 2012 end-page: 904 article-title: Identification of suitable reference genes for qPCR analysis of serum microRNA in gastric cancer patients publication-title: Dig Dis Sci – volume: 104 start-page: 1767 year: 2010 end-page: 74 article-title: Staging of non‐small cell lung cancer (NSCLC): a review publication-title: Respir Med – volume: 7 start-page: e38248 year: 2012 article-title: Low levels of cell‐free circulating miR‐361‐3p and miR‐625* as blood‐based markers for discriminating malignant from benign lung tumors publication-title: PLoS One – volume: 22 start-page: 309 year: 2003 end-page: 25 article-title: c‐Met: structure, functions and potential for therapeutic inhibition publication-title: Cancer Metastasis Rev – volume: 44 start-page: 216 year: 2011 end-page: 20 article-title: Cell‐free miR‐24 and miR‐30d, potential diagnostic biomarkers in malignant effusions publication-title: Clin Biochem – volume: 7 start-page: 1045 year: 2011 end-page: 55 article-title: miRNAs in lung cancer: large roles for small players publication-title: Future Oncol – volume: 127 start-page: 2859 year: 2010 end-page: 69 article-title: Downregulated microRNAs in the differential diagnosis of malignant pleural mesothelioma publication-title: Int J Cancer – volume: 56 start-page: 1 year: 2006 end-page: 51 article-title: Biological activity and biotechnological aspects of peptide nucleic acid publication-title: Adv Genet – volume: 42 start-page: 224 year: 2010 end-page: 8 article-title: Diagnostic value of Her‐2/neu, Cyfra 21‐1, and carcinoembryonic antigen levels in malignant pleural effusions of lung adenocarcinoma publication-title: Pathology – volume: 21 start-page: 398 year: 2007 end-page: 405 article-title: Diagnostic utility of pleural fluid carcinoembryonic antigen and CYFRA 21‐1 in patients with pleural effusion: a systematic review and meta‐analysis publication-title: J Clin Lab Anal – volume: 7 start-page: 459 year: 2012 end-page: 67 article-title: MET signaling: novel targeted inhibition and its clinical development in lung cancer publication-title: J Thorac Oncol – ident: e_1_2_7_28_1 doi: 10.1373/clinchem.2010.147405 – ident: e_1_2_7_22_1 doi: 10.1371/journal.pone.0038248 – volume: 4 start-page: 320 year: 1991 ident: e_1_2_7_5_1 article-title: Diagnostic efficacy of pleural biopsy as compared with that of pleural fluid examination publication-title: Mod Pathol contributor: fullname: Nance KV – ident: e_1_2_7_46_1 doi: 10.1016/S0065-2660(06)56001-8 – ident: e_1_2_7_14_1 doi: 10.1016/j.febslet.2010.08.009 – ident: e_1_2_7_26_1 doi: 10.1038/nrclinonc.2011.76 – ident: e_1_2_7_40_1 doi: 10.1023/A:1023768811842 – ident: e_1_2_7_8_1 doi: 10.1183/09031936.06.00013706 – ident: e_1_2_7_38_1 doi: 10.1016/j.febslet.2011.05.042 – ident: e_1_2_7_36_1 doi: 10.1007/s10620-011-1981-7 – ident: e_1_2_7_18_1 doi: 10.2217/fon.11.74 – ident: e_1_2_7_39_1 doi: 10.1002/gcc.20604 – ident: e_1_2_7_17_1 doi: 10.1016/j.bbcan.2009.11.003 – ident: e_1_2_7_19_1 doi: 10.1016/j.mrfmmm.2011.04.002 – ident: e_1_2_7_32_1 doi: 10.1373/clinchem.2008.112797 – ident: e_1_2_7_44_1 doi: 10.1158/0008-5472.CAN-08-1643 – ident: e_1_2_7_25_1 doi: 10.3389/fgene.2011.00007 – ident: e_1_2_7_4_1 doi: 10.1016/j.rmed.2010.08.005 – ident: e_1_2_7_33_1 doi: 10.1371/journal.pone.0039309 – ident: e_1_2_7_37_1 doi: 10.1002/hep.22158 – ident: e_1_2_7_13_1 doi: 10.1016/S0092-8674(04)00045-5 – ident: e_1_2_7_20_1 doi: 10.1515/CCLM.2011.661 – ident: e_1_2_7_2_1 doi: 10.3322/caac.20107 – ident: e_1_2_7_3_1 doi: 10.1183/09031936.01.00225601 – volume: 6 start-page: 211 year: 2010 ident: e_1_2_7_23_1 article-title: Free circulating nucleic acids in plasma and serum (CNAPS) -- Useful for the detection of lung cancer patients? publication-title: Cancer Biomark doi: 10.3233/CBM-2009-0131 contributor: fullname: Fleischhacker M – ident: e_1_2_7_31_1 doi: 10.1186/gb-2009-10-6-r64 – ident: e_1_2_7_12_1 doi: 10.1038/nature02871 – ident: e_1_2_7_11_1 doi: 10.1634/theoncologist.10-7-501 – ident: e_1_2_7_34_1 doi: 10.1186/1471-2199-9-76 – ident: e_1_2_7_10_1 doi: 10.1002/jcla.20208 – ident: e_1_2_7_43_1 doi: 10.1016/j.lungcan.2011.06.004 – ident: e_1_2_7_42_1 doi: 10.1016/j.lungcan.2011.07.008 – ident: e_1_2_7_7_1 doi: 10.1016/S0140-6736(03)13079-6 – ident: e_1_2_7_16_1 doi: 10.1016/j.biocel.2009.12.014 – ident: e_1_2_7_29_1 doi: 10.1186/1471-2407-10-591 – ident: e_1_2_7_27_1 doi: 10.1016/j.mrfmmm.2011.03.004 – ident: e_1_2_7_15_1 doi: 10.1016/j.coph.2010.05.010 – ident: e_1_2_7_41_1 doi: 10.1097/JTO.0b013e3182417e44 – ident: e_1_2_7_35_1 doi: 10.1038/sj.bjc.6606076 – volume: 41 start-page: 19 year: 2000 ident: e_1_2_7_6_1 article-title: The diagnostic yield of pleural fluid cytology in malignant pleural effusions publication-title: Singapore Med J contributor: fullname: Ong KC – ident: e_1_2_7_24_1 doi: 10.1586/era.11.197 – ident: e_1_2_7_30_1 doi: 10.1016/j.clinbiochem.2010.11.002 – ident: e_1_2_7_45_1 doi: 10.2174/1381612013397087 – ident: e_1_2_7_9_1 doi: 10.3109/00313021003631320 – ident: e_1_2_7_21_1 doi: 10.1002/ijc.25285 |
| SSID | ssj0011504 |
| Score | 2.4224706 |
| Snippet | Circulating cell‐free microRNAs (miRNAs) are potential cancer biomarkers. The aim of this study was to identify miRNAs that are differentially expressed... Circulating cell-free microRNAs (miRNAs) are potential cancer biomarkers. The aim of this study was to identify miRNAs that are differentially expressed... |
| SourceID | proquest crossref pubmed pascalfrancis wiley |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 645 |
| SubjectTerms | Adenocarcinoma - diagnosis Adenocarcinoma - genetics Adenocarcinoma of Lung Adult Aged Aged, 80 and over Antigens, Neoplasm - blood Biological and medical sciences Biomarkers Biomarkers, Tumor - blood Biomarkers, Tumor - genetics Cancer Carcinoembryonic Antigen - blood CEA Confidence intervals CYFRA 21‐1 Diagnosis, Differential Down-Regulation Female Humans Keratin-19 - blood lung adenocarcinoma Lung cancer Lung Neoplasms - diagnosis Lung Neoplasms - genetics Male Medical sciences MicroRNAs - blood Middle Aged miR‐198 Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Oligonucleotide Array Sequence Analysis Pediatrics pleural effusion Pleural Effusion, Malignant - diagnosis Pleural Effusion, Malignant - genetics Pneumology ROC Curve Tumors Tumors of the respiratory system and mediastinum Young Adult |
| Title | Downregulation of cell‐free miR‐198 as a diagnostic biomarker for lung adenocarcinoma‐associated malignant pleural effusion |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fijc.28054 https://www.ncbi.nlm.nih.gov/pubmed/23354517 https://www.proquest.com/docview/1433126143 https://search.proquest.com/docview/1354791607 |
| Volume | 133 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5VPSAkxPuRUiqDOHDJNrGdh8UJtVSlUjlUVOoBKbLjcVVod1fZ3UtP8A_4jfwSxnaSahFIiJsljy3H43k5428AXlusVYWIqdSOp7KyimSOGIJV4fOpKoMBp_v4Y3l4Ko_OirMNeDu8hYn4EOOFm5eMoK-9gGuz2L0BDb340k54TR4H6d9cVD6da_9khI7yjk6PwJylFIiVA6pQxnfHkWu26M5cL2hbXKxn8SeHc91_DQbo4B58HpYe806-TlZLM2mvf0N1_M9vuw93e8eUvYsn6QFs4PQh3Druf70_gu_7FK93sXI98ZLNHPOX_j-__XAdIru6OKFmrmqmF0wzGzP4aC7mH_j7HKCOkX_MLkm5ME3KjmxoRzNTH43T_SFBy64oMDj32TlsfokeE4Shcyt_p_cYTg_ef9o7TPv6DWkrpZJpLVBIrTJhSzQmtzKTzvG8dQaFy9GSAXUaFS_rkoIq1JJCU2Wcaa2R3PFSPIHN6WyKz4A5DLXSBFoiqnVrMtP6nEiuCtLWyBN4NXCymUeYjiYCMvOGNrMJm5nAzhqPR0qKzIOnmsD2wPSmF-UFxUZC5BRnSpHAy7GbhNBvsp7ibEU0opCV8lh9CTyNh-VmckGdRU49bwLL_76-5sPRXmhs_Tvpc7jNQ4EOn5K4DZvLboUvyE1amp0gD78AOYkRRA |
| link.rule.ids | 315,783,787,1378,27936,27937,46306,46730 |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIgESKq8CKaUYxIFLtontPCxxQS3VtnR7qFqpFxTZyRgV2t1VdvfCCf4Bv7G_pGPnUS0CCXGz5Iccj-eZ8TcAbyvMVYaIodSWhzKrFPEcEQSzxOVTZQY9TvfoKB2eyoOz5GwF3ndvYRp8iD7g5jjDy2vH4C4gvX2DGnr-tRzwnEyOW3Cb2F24wg27xz14lDN1WgzmKCRXLO1whSK-3U9d0kb3p3pGB2ObihZ_MjmXLVivgvYewOdu803mybfBYm4G5fffcB3_9-sewlprm7IPzWV6BCs4fgx3Ru3f9yfwc5dc9ropXk_kZBPLXNz_6scvWyOyy_NjasYqZ3rGNKuaJD5ai7k3_i4NqGZkIrMLki9Mk7wjNVrTytRH83R7T7Bil-QbfHEJOmx6gQ4WhKG1CxfWW4fTvY8nO8OwLeEQllIqGeYChdQqElWKxsSVjKS1PC6tQWFjrEiHWo2Kp3lKfhVqSd6pMtaUlZHc8lQ8hdXxZIzPgVn05dIEVjQo16WJTOnSIrlKSGAjD-BNR8pi2iB1FA0mMy_oMAt_mAFsLRG5H0nOuTdWA9jsqF603Dwj90iImFxNKQJ43XcTH7pD1mOcLGiMSGSmHFxfAM-a23KzuKDOJKaed57mf99fsX-w4xsb_z70FdwdnowOi8P9o08v4B739TpchuImrM7rBb4kq2lutjxzXAMi1xVc |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIlVIiPcjUIpBHLhkm9jOS5xQy6ottEIVlXpAiux4jArt7iq7e-EE_4DfyC9hbCepFoGEuFnyQ86Mx_7GGX8D8MJgWRWIGEtleSwLU5HNkUKwyFw8VaHR83QfHuV7J_LgNDtdg1f9W5jADzFcuDnL8Pu1M_CZsduXpKFnn5sRLwlxXIGrMifk6xDR8cAd5ZBOR8GcxOSJ5T2tUMK3h64rh9H1mZqTXGxIaPEnxLkKYP0JNL4JH_u5h8CTL6PlQo-ar7_ROv7nx92CGx0yZa_DUroNazi5AxuH3b_3u_B9lxz2NqSuJ2WyqWXu1v_ntx-2RWQXZ8dUTKuSqTlTzIQQPhqLuRf-LgioZQSQ2TntLkzRbkeHaEsjUx31U90qQcMuyDP45MJz2OwcHSkIQ2uX7lLvHpyM33zY2Yu7BA5xI2Ul41KgkKpKhMlR69TIRFrL08ZqFDZFQyeoVVjxvMzJq0IlyTettNWN0ZJbnov7sD6ZTvAhMIs-WZpAQ41K1ehENy4oklcZbdfII3jea7KeBZ6OOjAy85qEWXthRrC1ouOhJbnmHqpGsNkrve5seU7OkRApOZpSRPBsqCYrdEJWE5wuqY3IZFE5sr4IHoTFcjm4oMospZqXXuV_n1-9f7DjC4_-velT2Hi_O67f7R-9fQzXuE_W4cITN2F90S7xCUGmhd7ypvEL4gsUCw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Downregulation+of+cell-free+miR-198+as+a+diagnostic+biomarker+for+lung+adenocarcinoma-associated+malignant+pleural+effusion&rft.jtitle=International+journal+of+cancer&rft.au=HAN%2C+Hye-Suk&rft.au=JIEUN+YUN&rft.au=SEOK+JOONG+YUN&rft.au=KIM%2C+Wun-Jae&rft.date=2013-08-01&rft.pub=Wiley-Blackwell&rft.issn=0020-7136&rft.eissn=1097-0215&rft.volume=133&rft.issue=3&rft.spage=645&rft.epage=652&rft_id=info:doi/10.1002%2Fijc.28054&rft.externalDBID=n%2Fa&rft.externalDocID=27406508 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0020-7136&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0020-7136&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0020-7136&client=summon |